Literature DB >> 33177193

The Vaccinia Virus B12 Pseudokinase Represses Viral Replication via Interaction with the Cellular Kinase VRK1 and Activation of the Antiviral Effector BAF.

Amber B Rico1,2, Alexandria C Linville1,3, Annabel T Olson1,3, Zhigang Wang1,2, Matthew S Wiebe4,2.   

Abstract

The poxviral B1 and B12 proteins are a homologous kinase-pseudokinase pair, which modulates a shared host pathway governing viral DNA replication and antiviral defense. While the molecular mechanisms involved are incompletely understood, B1 and B12 seem to intersect with signaling processes mediated by their cellular homologs termed the vaccinia-related kinases (VRKs). In this study, we expand upon our previous characterization of the B1-B12 signaling axis to gain insights into B12 function. We begin our studies by demonstrating that modulation of B12 repressive activity is a conserved function of B1 orthologs from divergent poxviruses. Next, we characterize the protein interactome of B12 using multiple cell lines and expression systems and discover that the cellular kinase VRK1 is a highly enriched B12 interactor. Using complementary VRK1 knockdown and overexpression assays, we first demonstrate that VRK1 is required for the rescue of a B1-deleted virus upon mutation of B12. Second, we find that VRK1 overexpression is sufficient to overcome repressive B12 activity during B1-deleted virus replication. Interestingly, we also evince that B12 interferes with the ability of VRK1 to phosphoinactivate the host defense protein BAF. Thus, B12 restricts vaccinia virus DNA accumulation in part by repressing the ability of VRK1 to inactivate BAF. Finally, these data establish that a B12-VRK1-BAF signaling axis forms during vaccinia virus infection and is modulated via kinases B1 and/or VRK2. These studies provide novel insights into the complex mechanisms that poxviruses use to hijack homologous cellular signaling pathways during infection.IMPORTANCE Viruses from diverse families encode both positive and negative regulators of viral replication. While their functions can sometimes be enigmatic, investigation of virus-encoded, negative regulators of viral replication has revealed fascinating aspects of virology. Studies of poxvirus-encoded genes have largely concentrated on positive regulators of their replication; however, examples of fitness gains attributed to poxvirus gene loss suggests that negative regulators of poxvirus replication also impact infection dynamics. This study focuses on the vaccinia B12 pseudokinase, a protein capable of inhibiting vaccinia DNA replication. Here, we elucidate the mechanisms by which B12 inhibits vaccinia DNA replication, demonstrating that B12 activates the antiviral protein BAF by inhibiting the activity of VRK1, a cellular modulator of BAF. Combined with previous data, these studies provide evidence that poxviruses govern their replication by employing both positive and negative regulators of viral replication.
Copyright © 2021 American Society for Microbiology.

Entities:  

Keywords:  B1; BAF; VRK; poxvirus; protein kinases

Mesh:

Substances:

Year:  2021        PMID: 33177193      PMCID: PMC7925102          DOI: 10.1128/JVI.02114-20

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  65 in total

Review 1.  The secret life of kinases: insights into non-catalytic signalling functions from pseudokinases.

Authors:  Annette V Jacobsen; James M Murphy
Journal:  Biochem Soc Trans       Date:  2017-06-15       Impact factor: 5.407

2.  Identification of rpo30, a vaccinia virus RNA polymerase gene with structural similarity to a eucaryotic transcription elongation factor.

Authors:  B Y Ahn; P D Gershon; E V Jones; B Moss
Journal:  Mol Cell Biol       Date:  1990-10       Impact factor: 4.272

3.  Vaccinia Virus Encodes a Novel Inhibitor of Apoptosis That Associates with the Apoptosome.

Authors:  Melissa R Ryerson; Monique M Richards; Marc Kvansakul; Christine J Hawkins; Joanna L Shisler
Journal:  J Virol       Date:  2017-11-14       Impact factor: 5.103

4.  Vaccinia Virus B1 Kinase Is Required for Postreplicative Stages of the Viral Life Cycle in a BAF-Independent Manner in U2OS Cells.

Authors:  Augusta Jamin; Nouhou Ibrahim; April Wicklund; Kaitlin Weskamp; Matthew S Wiebe
Journal:  J Virol       Date:  2015-07-29       Impact factor: 5.103

Review 5.  Diverse cellular functions of barrier-to-autointegration factor and its roles in disease.

Authors:  Rhiannon M Sears; Kyle J Roux
Journal:  J Cell Sci       Date:  2020-08-17       Impact factor: 5.285

6.  Characterization of three paralogous members of the Mammalian vaccinia related kinase family.

Authors:  R Jeremy Nichols; Paula Traktman
Journal:  J Biol Chem       Date:  2003-11-25       Impact factor: 5.157

Review 7.  Emerging roles of pseudokinases.

Authors:  Jérôme Boudeau; Diego Miranda-Saavedra; Geoffrey J Barton; Dario R Alessi
Journal:  Trends Cell Biol       Date:  2006-08-01       Impact factor: 20.808

8.  Poxviruses deploy genomic accordions to adapt rapidly against host antiviral defenses.

Authors:  Nels C Elde; Stephanie J Child; Michael T Eickbush; Jacob O Kitzman; Kelsey S Rogers; Jay Shendure; Adam P Geballe; Harmit S Malik
Journal:  Cell       Date:  2012-08-17       Impact factor: 41.582

9.  Vaccinia virus protein N2 is a nuclear IRF3 inhibitor that promotes virulence.

Authors:  Brian J Ferguson; Camilla T O Benfield; Hongwei Ren; Vivian H Lee; Gordon L Frazer; Pavla Strnadova; Rebecca P Sumner; Geoffrey L Smith
Journal:  J Gen Virol       Date:  2013-06-12       Impact factor: 3.891

10.  Depletion of the protein kinase VRK1 disrupts nuclear envelope morphology and leads to BAF retention on mitotic chromosomes.

Authors:  Tyler P Molitor; Paula Traktman
Journal:  Mol Biol Cell       Date:  2014-01-15       Impact factor: 4.138

View more
  1 in total

1.  Dysregulation of Cellular VRK1, BAF, and Innate Immune Signaling by the Vaccinia Virus B12 Pseudokinase.

Authors:  Alexandria C Linville; Amber B Rico; Helena Teague; Lucy E Binsted; Geoffrey L Smith; Jonas D Albarnaz; Matthew S Wiebe
Journal:  J Virol       Date:  2022-05-11       Impact factor: 6.549

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.